



Established 1947

NASDAQ:ACET

*Global Leader in the Sourcing, Quality Assurance, Regulatory Support,
Marketing and Distribution of Pharmaceuticals, Nutraceuticals, Specialty
Chemicals and Crop Protection Products*

“Enabling Quality Worldwide”™



Rising Pharmaceuticals Transaction

January 6, 2011



This presentation may contain forward-looking statements as that term is defined in the federal securities laws. All statements that address expectations or projections about the future are forward looking statements. Although they reflect our current expectations, these statements are not guarantees of future performance but involve a number of risks and assumptions. We urge you to review Aceto's filings with the SEC including, but not limited to, Aceto's Annual Report on Form 10-K for the fiscal year ended June 30, 2010 for discussion of some of the factors that could cause actual results to differ materially. Copies of these filings are available at www.sec.gov. We do not undertake any duty to update any forward looking statement.


Strategic Overview

- This transaction represents a natural expansion and a significant step for Aceto by establishing another platform for our growth in the Health Sciences arena
- We had identified that further expansion of our finished dosage form product offerings from both foreign and domestic facilities complements our core strength of sourcing active pharmaceutical ingredients
- We now have a presence as a “developer”, “marketer” and “brand” of generic pharmaceuticals
- We believe that this combination of sourcing capabilities and marketing allows us to provide greater benefits to both Aceto and Rising suppliers and customers



Rising Pharmaceuticals & Aceto Corporation Stronger Together

January 6, 2011



Specialty Generics Focus

- Rising is focused on the marketing and distribution of quality generic products packaged under the “Rising” label
- Rising is dedicated to providing competitively priced generic pharmaceutical products to meet the ever changing needs of their customers through a commitment to quality, innovation and integrity



Rising's Roots – Similar to Aceto

- Rising started out in the 1970's by representing companies such as Par Pharmaceuticals, Hi-Tech Pharmacal, Invamed, Able, Ford Labs, Twinlab, NBTY and many other pharmaceutical and nutritional companies to chains, wholesalers and distributors. (Aceto started out by being a manufacturer's representative)
- In the early 1990's, focus shifted to the development of our "own labeled" generic products and partnering with emerging generic manufacturers for the co-development of ANDA's. (At the same time, Aceto moved towards being an independent distributor)



Rising at a Glance

- 40 years of experience in the US generics market.
- The “Rising” label has a strong brand recognition among pharmacists and buyers of pharmaceutical products with a reputation for excellence.
- Currently offer 35 commercial products.
- Multiple dosage forms and therapeutic categories
 - Rx
 - Controlled Drugs
 - OTC’s
- 11 active ANDA projects pending at FDA.
- 20 generic products in various stages of development in partnership with selected contract manufacturers.



Facilities

- Allendale, NJ Headquarters
 - 34,000 sq. ft. of rented space
 - Offices
 - Distribution Center
- Temperature Controlled Warehousing
- cGMP warehousing operation for Finished Dosage Forms, OTC and Rx Products
- Strong compliance track record; no 483's
- Excellent Systems Infrastructure



Customers



Business Model


- A strong experienced national sales and marketing team for Rising products that cultivates long-term relationships with buyers at major chains, wholesalers, and other key distributors
- Building and maintaining partnerships with talented formulators, pharmaceuticals developers and manufacturers of finished dosage form products across dosage forms
- Identifying attractive, specialty product opportunities
- Managing all of the processes necessary to support a U.S. based cGMP distribution and marketing center



Business Development

- Rising has a strong track record identifying attractive product opportunities
 - Close to the customer – providing access to market opportunities and market feedback
 - As long-term players in the market, “deal flow” from many generic manufacturers are brought to our attention
 - Business Development team maintains extensive contacts among API, CRO and other industry organizations
 - Using multiple industry databases, seek “niche” opportunities fitting sales and financial objectives

Rising to the Challenge



RISING TO THE CHALLENGE

Rising is focused on marketing high quality multi-source pharmaceuticals that make sense for you and your customers. With a robust pipeline of ANDAs in development, Rising is the choice for your next product challenge.

www.risingpharma.com

 **Rising**
Pharmaceuticals, Inc.

© Rising Pharmaceuticals, Inc. 2005

1.866.TO RISING



Rising Transaction – Financial Highlights

- Transaction value of \$80 Million includes receipt of \$5 Million in working capital
- This represents an EBITDA multiple of slightly less than 7.2 based on Rising's projected calendar year earnings inclusive of royalty income and before seller transaction charges and one-off items
- Rising's calendar year 2010 net revenue were approximately \$42 Million which included royalty income of \$4.5 Million but excludes \$4.2 million of other income



Funding the Transaction

- Aceto has funded the transaction with a loan from its senior bank facility of \$50 Million, repatriated cash from foreign operations of \$13.9 Million and issuance of 1 Million shares of common stock valued at \$8.1 Million
- The transaction requires a deferred purchase price consideration of \$8 Million to be paid over the next four years as well as an additional contingent payout, depending on financial accretive performance, of up to \$6 Million payable after the fourth year anniversary
- The Company has entered into a Senior Credit Agreement with JPMorgan Chase Bank, N.A. and Wells Fargo with JPMorgan Chase acting as Administrative Agent for \$80 Million
- Direct cost relating to this transaction are expected to be approximately \$1.4 Million and tax of approximately \$2.6 Million on repatriated cash (earnings) will be reported in the quarter ending December 31, 2010. Seller's transaction costs were incurred by the Seller.



Rising Pharmaceuticals, Inc.

- Rising will be managed as a stand alone subsidiary
- For confidential competitive reasons their financial results will be included in our Health Sciences Segment

